Ara
Toplam kayıt 42, listelenen: 11-20
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
(Wiley, 2023)
The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese.
Pathogenetic pathways in nonalcoholic fatty liver disease: An incomplete jigsaw puzzle
(Elsevier, 2023)
Multiple pathways including insulin signaling, JNK1/2 of MAPK signaling, GLP-1R signaling, and NRs affect to maintain the homeostasis of lipid metabolism in normal liver. ERK1/2 and P38 of MAPK signaling pathway antagonistically ...
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
(Lippincott Williams & Wilkins, 2023)
Background:Liver biopsy for the diagnosis of non-alcoholic steatohepatitis (NASH) is limited by its inherent invasiveness and possible sampling errors. Some studies have shown that cytokeratin-18 (CK-18) concentrations may ...
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry (TM)
(Wiley, 2023)
Chronic hepatitis B (CHB) infection is one of the most common causes of cirrhosis and liver cancer worldwide. Our aim was to assess clinical and patient-reported outcome (PRO) profile of CHB patients from different regions ...
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
(Kare Publishing, 2023)
Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ...
The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients
(Kare Publishing, 2023)
Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.Materials ...
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply
(Wiley, 2023)
We appreciate the editorial comments by Drs. Sun and Fan about our study assessing the associations of patient-reported outcomes (PROs) and non-invasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) ...
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
(Elsevier, 2022)
Background & Aims: Non-invasive tests (NITs) offer a practical solution for advanced fibrosis identification in non-alcoholic
fatty liver disease (NAFLD). Despite increasing implementation, their use is not standardised, ...
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
(Kare Publishing, 2023)
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
(Wolters Kluwer Medknow Publications, 2023)
Background and Aims: We evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in NAFLD patients with type 2 diabetes (T2D). Methods and Results: This was an individual patient data meta-analysis of 1780 ...